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Since vancomycin-resistant enterococci (VRE)
were first reported in the late 1980s, their
geographic distribution and importance as
nosocomial pathogens have continued to in-
crease worldwide. In the United States, the
percentage of states with a National Nosocomial
Infections Surveillance System hospital report-
ing one or more patients with VRE infection
increased from 27% (19891993) to 44% (1994
1995) (1). Among enterococci causing infection in
these hospitals, the percentage resistant to
vancomycin increased from 0.4% (1989) to 10.8%
(1995) in intensive care unit patients and from
0.3% (1989) to 10.4% (1995) in nonintensive care
unit patients (1).
Although early detection of VRE is important
for preventing its spread among hospitalized
patients, clinical laboratories in the United
States have difficulty detecting VRE, especially
those with intermediate or low-level resistance,
characteristic of VRE with the VanB phenotype
(2,3). Certain automated and manual antimicro-
bial susceptibility test systems are associated
with the inability of laboratories to detect VRE.
Laboratories outside the United States (e.g., in
Argentina [4]) may have difficulty detecting VRE
for largely the same reasons: limitations of
susceptibility test systems. In addition, laborato-
ries outside the United States, Canada, and
Europe may face language and financial barriers
to accessing information important for updating
their methods and optimizing VRE detection.
No VRE have been reported from hospitals in
Mexico. However, because VRE have been
reported from hospitals in Texas, and VanB has
been described as the predominant phenotype in
at least one hospital in the Houston area (5), we
assessed the ability of clinical laboratories in and
near Monterrey (in northeastern Mexico) to
detect VRE.
Study Protocol
The laboratory survey and data collection
were performed in July-August 1997. Five
strains of enterococci (two Enterococcus faecium,
two  E. faecalis, one E. gallinarum), with or
without resistance to vancomycin, were coded as
isolates 1 through 5 (Table). Four of these had
been used in proficiency surveys in the United
States (3) and Argentina (4). The fifth isolate
came from the American Type Culture Collection
(ATCC 29212). The isolates were distributed,
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Early detection of vancomycin-resistant enterococci is important for preventing its
spread among hospitalized patients. We surveyed the ability of eight hospital
laboratories in and near Monterrey, Mexico, to detect vancomycin resistance in
Enterococcus spp. and found that although laboratories can reliably detect high-level
vancomycin resistance, many have difficulty detecting low-level resistance.
Table. Characteristics of enterococcal study isolates and
results of enterococcal susceptibility testing, by category
No. of labsa
Isolate no. MIC Vancomycin (n = 8)
and species (µg/ml) phenotype S I R
1. E. faecium 512 VanA 0 0 8b
2. E. faecium   64 VanB-like 2 1 5b
3. E. faecalis   16-32 VanB 2 1b 5b
4. E. gallinarum    8 VanC 1 5b 2
5. E. faecalis   £4 Susceptible 7b 10
a Laboratories reporting susceptibility to vancomycin;
S = susceptible, I = intermediate, R = resistant.
bCorrectly identified.144 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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along with standardized susceptibility test
results forms, to eight clinical laboratories
(seven within and one near Monterrey).
Laboratories were blinded to the susceptibil-
ity patterns of the isolates and asked to test the
five isolates for resistance to vancomycin with
the antimicrobial susceptibility testing method
they routinely used. The laboratorians recorded
disk zone sizes or MICs and their interpretation
of the results (susceptible, intermediate, or
resistant), in addition to species identification
methods used, zone size breakpoints used for
disk diffusion, existence of an antimicrobial
control program, and hospital demographic
characteristics. No information was collected
regarding the version of software program used
with automated susceptibility test systems. The
Centers for Disease Control and Prevention
(CDC) analyzed the forms and classified errors in
vancomycin susceptibility testing as very major
(reporting a resistant strain as susceptible),
major (reporting a susceptible strain as
resistant), minor (reporting an intermediate or
resistant strain as susceptible or intermediate,
respectively), or very minor (reporting a
susceptible or intermediate strain as intermedi-
ate or resistant, respectively).
MICs were determined by broth microdilution
and disk diffusion testing (3). In addition, a
polymerase chain reaction assay was used to
confirm the presence of the vanA resistance
determinant in organism 1 (3).
Study Findings
The eight participating laboratories each
serviced one hospital with a median bed count of
148 (70 to 185). All but one hospital had neonatal,
pediatric, and adult intensive care units; half
were teaching hospitals. Only two laboratories
reported an antimicrobial use control program in
place in their hospital.
The antimicrobial susceptibility testing
methods used were the Sceptor system (Becton-
Dickinson Microbiology Systems, Cockeysville,
MD) (three laboratories); Vitek (bioMerieux, St.
Louis, MO) (two); standard disk diffusion (two);
and Microscan Autoscan (Dade International,
West Sacramento, CA) (one). Of the two
laboratories that used disk diffusion, one used
outdated breakpoint zone sizes; the other used
breakpoints currently recommended by the
National Committee for Clinical Laboratory
Standards (NCCLS).
Vancomycin Resistance Detection
All laboratories correctly detected the high-
level vancomycin resistance in isolate 1 (high-
level vancomycin resistance [MIC 512 µg/ml] of
the VanA phenotype) (Table). Only five
laboratories reliably detected the low-level
resistance (MIC 64 µg/ml) typical of the VanB-
like phenotype possessed by isolate 2; laborato-
ries made two very major errors reporting this
resistant isolate as susceptible. Six laboratories
correctly categorized isolate 3 with the VanB
phenotype (MIC 16-32 µg/ml) as intermediate or
resistant; two laboratories committed minor
errors by reporting this isolate as susceptible.
Five laboratories correctly categorized isolate 4;
one laboratory committed a minor error, and two
laboratories committed very minor errors. Of the
eight laboratories, seven correctly identified
vancomycin susceptibility in isolate 5.
Of the 15 test results from the three hospitals
using the Sceptor system, 3 (20%) were errors
(all minor). Of the 10 results from the two
hospitals using disk diffusion, four (40%) were
errors. The laboratory using outdated NCCLS
zone-size breakpoints committed one very major
and one very minor error; the laboratory using
the current NCCLS breakpoints committed two
very minor errors. The two hospitals using the
Vitek automated system generated 10 vancomy-
cin susceptibility test results; two were errors
(one very major and one minor).
Species Identification
Of the participating laboratories, three used
the Sceptor system to identify species, two used
the Vitek system, one used Microscan Autoscan,
one used the Pasco system (Difco, Wheatridge,
CO), and one did not report its identification
method. Seven laboratories correctly identified
isolates 1 and 2, both E. faecium; five
laboratories correctly identified isolate 3, an
E. faecalis; none correctly identified isolate 4, an
E. gallinarum (six laboratories identified it as
E. faecalis and two as E. faecium); and all
laboratories correctly identified isolate number
5, an E. faecalis.
Conclusions
Because VRE may be transmitted easily by
health-care workers from infected to uninfected
patients, who may become colonized and serve as
reservoirs for transmission, the delay caused by
failure of the laboratory to detect VRE from an145 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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infected patient may facilitate the emergence of
VRE in a hospital or a group of hospitals in a
geographic region. Early studies suggested
laboratories were more likely to miss intermedi-
ate- or low-level vancomycin resistance in
enterococci if they relied on commercial
automated test systems (3,6). More recent
studies suggest persistent problems with the
Vitek instrument (2). In addition, disk diffusion
is not sufficiently sensitive in detecting low- and
intermediate-level resistance to vancomycin
when used as the sole method (2,4). Despite
revision of NCCLS-recommended breakpoint
zone sizes (7), disk diffusion remains relatively
insensitive, possibly because susceptible and
resistant zone sizes cluster around breakpoints.
In addition, laboratory personnel may not
consistently follow recommendations to read
plates with transmitted light after a full 24
hours incubation (7). Microscan has shown
improved performance (2), likely due to software
and hardware revisions (6).
Of the 40 test results in our study, 9 (23%)
were erroneous compared with results at CDC; 2
(5%) were very major errors. In comparison, of
335 vancomycin susceptibility test results in 67
New Jersey laboratories, 111 (33%) were
erroneous, with 20 (6%) very major errors (3). Of
25 vancomycin susceptibility test results in four
Argentine laboratories, 11 (44%) were errone-
ous, with 2 (8%) very major errors (4). Although
our results compared favorably with those of the
New Jersey and Argentina studies, which used
four test strains we used, the rate of very major
errors is unacceptably high, especially for low-
level resistance.
Some errors may have been caused by
inadequately skilled personnel. One laboratory
was using outdated zone-size breakpoints,
despite 1992 revisions, a reminder that
instituting contemporary methods in some
laboratories may be difficult and lead to incorrect
epidemiologic data. However, the overall lower
error rate compared with previous studies and
the association of errors with certain test
methods suggest that limitations of test methods
were primarily responsible for inaccuracies. Too
few vancomycin susceptibility tests were
performed to ascertain relative performance of
test methods. However, the 20% error rate and
lack of major errors obtained by the Sceptor
system, compared with higher error rates and
very major errors from laboratories that used the
Vitek and disk diffusion methods, are consistent
with previous results (8).
NCCLS recommends the use of an agar
screen plate consisting of brain heart infusion
agar containing 6  µg/ml of vancomycin to detect
low- and intermediate-level vancomycin resis-
tance (9). We recommend that laboratories in the
Monterrey area use a supplemental brain heart
infusion screening agar to test for vancomycin
resistance in enterococci isolated from selected
clinical specimens (e.g., blood, urine, sterile body
sites). Because screening agar has a sensitivity of
100% and specificity of 96% to 99% (2), we
recommend that isolates that grow on the
screening agar be reported as resistant unless
repeat testing with a reference MIC method
suggests otherwise.
Some enterococci (e.g., E. gallinarum and
E. caseliflavus), which have intermediate-level
vancomycin resistance known as the VanC
phenotype, rarely cause human infection.
Isolation of this form of VRE, therefore, does not
have the same public health importance as that
of vancomycin-resistant E. faecium or E. faecalis.
Therefore, to focus efforts on controlling
antimicrobial resistance in species likely to cause
serious human infection, laboratories must
correctly identify VRE to the species level. Both
E. gallinarum and E. casseliflavus can be
differentiated from other enterococci on the basis
of their motility. E. casseliflavus may be easily
differentiated from E. faecium or E. faecalis by
its yellow pigment; in contrast, E. gallinarum
may not be reliably identified unless a motility
test is performed with the appropriate media
(10). A new conventional biochemical test for
methyl-a-D-glycopyranoside (MDG) may be
even more reliable than motility in differentiat-
ing  E. gallinarum from E. faecium and
E. faecalis (11).
The laboratories difficulty in detecting low-
and intermediate-level vancomycin resistance
and in correctly identifying enterococci to the
species level, especially E. gallinarum, suggests
a need for additional tests to aid in the early
detection and correct identification of VRE.
Although no VRE have been reported from
Mexico, the study area is close to areas in the
United States where VRE have been reported
and the VanB phenotype may be predominant (5).146 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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